Remibrutinib Dose B
Sponsors
Novartis Pharmaceuticals
Conditions
Hidradenitis Suppurativa
Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Active, not recruitingNCT06799000
Start: 2025-01-31End: 2027-10-04Updated: 2026-08-20
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Active, not recruitingNCT06840392
Start: 2025-03-20End: 2027-10-21Updated: 2026-08-21